4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
31.86
-4.01 (-11.18%)
Mar 28, 2024, 4:00 PM EDT - Market closed

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
20.723.1318.0413.616.9914.13
Revenue Growth (YoY)
562.29%-82.65%32.52%94.85%-50.56%-
Gross Profit
20.723.1318.0413.616.9914.13
Selling, General & Admin
36.4932.9128.0117.2413.96.17
Research & Development
97.180.2561.3653.0438.7218.36
Other Operating Expenses
00005.140
Operating Expenses
133.59113.1689.3770.2857.7524.53
Operating Income
-112.87-110.03-71.33-56.66-50.76-10.4
Other Expense / Income
-12.03-2.54-0.020.03-1.46-0.85
Pretax Income
-100.84-107.49-71.32-56.69-49.31-9.55
Net Income
-100.84-107.49-71.32-56.69-49.31-9.55
Shares Outstanding (Basic)
393228655
Shares Outstanding (Diluted)
393228655
Shares Change
20.95%16.66%331.23%25.05%1.85%-
EPS (Basic)
-2.58-3.32-2.57-8.82-9.59-1.89
EPS (Diluted)
-2.58-3.32-2.57-8.82-9.59-1.89
Free Cash Flow
-78.56-98.22-78.24-51.91-39.91-16.67
Free Cash Flow Per Share
-2.01-3.04-2.82-8.07-7.76-3.30
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-544.65%-3516.52%-395.46%-416.28%-726.65%-73.60%
Profit Margin
-486.59%-3435.41%-395.37%-416.49%-705.78%-67.59%
Free Cash Flow Margin
-379.11%-3139.05%-433.77%-381.35%-571.34%-117.95%
EBITDA
-95.09-103.61-68.3-55.25-48.3-8.85
EBITDA Margin
-458.85%-3311.41%-378.63%-405.89%-691.41%-62.66%
Depreciation & Amortization
5.753.883.021.4410.7
EBIT
-100.84-107.49-71.32-56.69-49.31-9.55
EBIT Margin
-486.59%-3435.41%-395.37%-416.49%-705.78%-67.59%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).